Inogla

Inogla is a pharmaceutical drug for the treatment of type 2 diabetes mellitus. It belongs to the class of anti-diabetic drugs known as dipeptidyl peptidase-4 inhibitors or Gliptins.

With regard to general safety, Inogla has been well tolerated in short-term studies.

Inogla works by causing the pancreas to release more insulin and decreasing the hormones that cause blood sugar levels to rise.

Common side effects of Inogla are include;

• Headache
• Hypoglycemia
• Upper respiratory tract infection
• Nasopharyngitis
• Constipation
• Gastrointestinal symptoms
• Fatigue
• Kidney problems
• Skin rashes
• Itching
• Abdominal pain
• Loss of appetite

Inogla should be used during pregnancy only if necessary. The risk to the developing foetus is not known. Consult your doctor if you are pregnant before taking this medication.

Inogla may pass into breastmilk. Hence it is not recommended while breastfeeding. Consult your doctor if you are breastfeeding before taking this medication.

Avoid consuming alcohol while taking Inogla as alcohol consumption may lead to low blood sugar levels.

The Inogla may be taken on an empty stomach or with food. Make sure you just take in the sum stated at a given time, not more or less. 

Teneligliptin is given orally to adults in doses of 20 mg once daily, which can be increased to 40 mg per day.

The maximum percentage of the inhibition in plasma DPP-4 activity was achieved within 2 hours after administration and was 81.3% and 89.7% in the 10 and 20 mg Inogla groups, respectively.

Adults can take 20 mg of Inogla once a day in general. If the effect isn't strong enough, the dosage can be raised by up to 40 mg once a day.

Inogla has been systematically evaluated in T2DM as monotherapy with diet and exercise and in combination with metformin, glimepiride, pioglitazone, and insulin in short-term (12 weeks) and long-term (52 weeks) studies.

Inogla was well tolerated by subjects with hepatic impairment.

If your blood sugar levels are uncontrolled and complications like ketosis, diabetic coma or pre-coma have developed.

Available clinical evidence suggests that Inogla exerts cardiovascular safety in T2DM patients. This Inogla can be used in T2DM patients with CKD including end stage renal disease patients without any major safety concern.

Inogla may cause low blood sugar which can impair your ability to drive or operate heavy machines. Always keep sugar or chocolate with you while driving. In case you experience any of the symptoms of low blood sugar such as dizziness, drowsiness, sweating, stop driving immediately and have sugar.

If you have missed any dose of Inogla then take it as soon as you remember. If it is already time for the next dose then skip the missed dose and follow the regular dosing schedule. Do not take a double dose to compensate for the missed one.

Symptoms of overdose may include dizziness, fainting, sweating, tremors, confusion etc. Seek immediate medical help in case of an overdose.

Do not stop taking Inogla without talking to your doctor. If you stop taking Inogla suddenly your diabetes may get worse. If you want to stop taking your medicine, speak to your doctor. They may be able to suggest an alternative treatment for your diabetes.

The study reported that maximum plasma concentration following a single oral dose of 20 mg Inogla was unaffected by mild, moderate and severe renal impairment.